Annick Menetrey
Lausanne, VD, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Model-based quantification of immune response and anti-staphylococcal activity of afabicin in immunocompetent mouse thigh infections to enable predictions of clinical efficacy.
Journal: Antimicrobial agents and chemotherapy
Published: March 04, 2026
Identification, structural elucidation and nonclinical characterisation of oxMET1: a further major metabolite of xevinapant?
Journal: Xenobiotica; the fate of foreign compounds in biological systems
Published: February 16, 2026
In vitro-in vivo extrapolation of intrinsic clearance based on data from human hepatocyte spheroids - a case study with the low-clearance drug xevinapant.
Journal: Xenobiotica; the fate of foreign compounds in biological systems
Published: November 10, 2025
Absolute Bioavailability and Absorption, Distribution, Metabolism, and Excretion of [14C]Xevinapant, a Potent, Oral, Small-Molecule IAP Inhibitor.
Journal: Clinical pharmacology in drug development
Published: August 20, 2025
Model-based translation of results from in vitro to in vivo experiments for afabicin activity against Staphylococcus aureus.
Journal: The Journal of antimicrobial chemotherapy
Published: June 06, 2024
Exploratory window-of-opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer.
Journal: Clinical and translational science
Published: October 05, 2020
Bone and Joint Tissue Penetration of the Staphylococcus-Selective Antibiotic Afabicin in Patients Undergoing Elective Hip Replacement Surgery.
Journal: Antimicrobial agents and chemotherapy
Published: August 15, 2018
The effects of CYP3A4 induction and inhibition on the pharmacokinetics of alisporivir in humans.
Journal: Clinical pharmacology in drug development
Published: October 28, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026